Impurity C of Alfacalcidol

Impurity of Alfacalcidol. Alfacalcidol (1-hydroxycholecalciferol; Alpha D3; 1.alpha.-Hydroxyvitamin D3) is a non-selective VDR activator medication. IC50 value: Target: VDR activator Alfacalcidol (1-hydroxycholecalciferol; Alpha D3; 1.alpha.-Hydroxyvitamin D3) improves mechanical bone strength and bone mass; suppresses osteoclastic bone resorption in vivo.

Product Specifications

CAS Number

[82266-85-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

VD/VDR

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/impurity-c-of-alfacalcidol.html

Purity

99.81

Solubility

DMSO : 6.67 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

O[C@@H]1CC(C2C=C3[C@@](CC[C@@H]4[C@@H](CCCC(C)C)C)([H])[C@]4(C)CCC3N(C(N5C6=CC=CC=C6)=O)N2C5=O)=C(C)[C@@H](O)C1

Molecular Formula

C35H49N3O4

Molecular Weight

575.78

Precautions

H302, H315, H319, H335

References & Citations

[1]Shiraishi et al (2000) Alfacalcidol inhibits bone resorption and stmulates formation in an ovariectomized rat model of osteoporosis: Distinct actions from estrogen. Journal of Bone and Mineral Research. 15 770.|[2]Ringe JD, Schacht E. et al. Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol. Rheumatol Int. 2004 Jul;24 (4) :189-97.|[3]Ivarsen P, Povlsen JV, Christensen KL.Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: A pilot study.Scand J Urol Nephrol. 2012 Jun 25.|[4]Rianthavorn P, Pisutikul K, Deekajorndech T, Tepmongkol S, Suphapeetiporn K.Prevention of bone loss in children receiving long-term glucocorticoids with calcium and alfacalcidol or menatetrenone.J Pediatr Endocrinol Metab. 2012;25 (3-4) :307-12.